Milrinone Pinewood Laboratories (Milrinone)

Milrinone blocks the enzyme phosphodiesterase‑3, which normally degrades cyclic AMP. By preserving cAMP levels in heart muscle and vascular smooth muscle, it enhances calcium‑mediated contraction (positive inotropy) and promotes vasodilation, together improving blood flow and cardiac performance.

The dose of Milrinone is individualized by the prescribing clinician based on the patient’s weight, renal function, and hemodynamic status. A typical regimen involves a loading dose followed by a continuous intravenous infusion, but exact parameters are set by the treating physician.

The safety of Milrinone in pregnancy and lactation has not been established. It is classified as pregnancy category unknown, and the drug should only be used if the potential benefit justifies any potential risk to the fetus or infant. Consultation with a specialist is essential.

To request Milrinone, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Milrinone differs from catecholamine inotropes such as dopamine or dobutamine by acting via phosphodiesterase‑3 inhibition rather than adrenergic receptors. This mechanism provides both inotropic support and vasodilation, which can reduce afterload, whereas catecholamines primarily increase heart rate and may raise systemic vascular resistance.

Milrinone intravenous solution should be stored refrigerated at 2‑8 °C. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the container. If the product reaches room temperature, use it promptly according to the manufacturer’s guidance.

Milrinone is given exclusively by intravenous infusion. After a possible loading dose, a continuous infusion is maintained using an infusion pump, allowing precise control of the rate. Administration is performed by trained healthcare professionals in a monitored setting such as an intensive care unit.

The most serious risks include severe hypotension, life‑threatening ventricular arrhythmias, myocardial ischemia, and allergic reactions such as anaphylaxis. Continuous hemodynamic monitoring is essential to detect these events early and intervene appropriately.

Milrinone is contraindicated in patients with uncontrolled ventricular arrhythmias, severe aortic or mitral valve stenosis, or those who have had a recent myocardial infarction with ongoing ischemia. It should also be avoided in individuals with known hypersensitivity to milrinone or any component of the formulation.